Vivance is a patient-centric medical technology company with a mission to enhance the lives of people with kidney disease and their caregivers by providing solutions to deliver better outcomes along with improving their quality of life.
Vertex Pharmaceuticals
Vertex invests in scientific innovation to create transformative medicines for people with serious diseases. Through cutting-edge science across multiple modalities, it has approved medicines that treat the underlying causes of multiple diseases and conditions and has a broad and deep clinical pipeline. Learn more at www.vrtx.com. | Vertex, a global biotechnology company, invests in scientific innovation to create transformative medicines for people with serious diseases. It has approved medicines that treat the underlying causes of cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain and continues to advance its research in these areas. Vertex has a broad and deep clinical pipeline across a range of modalities for other serious diseases like type 1 diabetes, APOL1-mediated kidney disease and IgA nephropathy. | xxx | Vertex, a global biotechnology company, invests in scientific innovation to create transformative medicines for people with serious diseases. It has approved medicines that treat the underlying causes of cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain and continues to advance its research in these areas. Vertex has a broad and deep clinical pipeline across a range of modalities for serious kidney diseases, including APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy and autosomal dominant polycystic kidney disease.
Vera Therapeutics
Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious immunological and rare diseases. Vera’s mission is to advance treatments that target the source of disease in order to transform the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN), also known as Berger’s disease. Vera is also developing MAU868, a monoclonal antibody that neutralizes infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant.
Unicycive
UNICYCIVE was founded in August 2016 by Shalabh Gupta, MD, with the goal of building a company to solve the most pressing unmet medical needs in renal diseases. In 2018, Dr. Gupta licensed our first two technologies—UNI-494 and Oxylanthanum Carbonate (OLC)—with the help of a small but mighty team of industry-leading researchers and developers. Over the last five years our team has worked tirelessly to refine the technologies and help realize their full potential in patients with kidney diseases. In the process, we created a unique biotech system to prospect, unearth, refine, and create value with other technologies and in other disease states that also have pressing unmet medical needs. As we advance our existing technologies, we continue to look opportunistically for additional assets by identifying potential that others miss and partnering with promising therapeutic candidates that match our vision and mission. Our goal as an organization remains intently focused on bringing to market game-changing solutions quickly and efficiently for indications where patients continue to go underserved. At Unicycive, we know that only together can we advance science and medicine to make the biggest impact for patients, physicians, investors, and the healthcare community at large.
SAEPTUM
SÆPTUM is a pioneering French DeepTech company revolutionizing vascular access with its patented valve system. Integrated into five innovative devices – from CVC add-ons to long-term percutaneous solutions – this technology minimizes infection risks, simplifies patient care pathways, and enables self-homecare.With its groundbreaking HemoPlug™ technology, SÆPTUM enhances patient safety and streamlines infusion therapies, particularly for dialysis. By reducing complications and facilitating easier treatments, its solutions empower both healthcare professionals and patients.Guided by its motto, ‘Designed for Care,’ SÆPTUM is committed to improving vascular access with cutting-edge innovation. Its multidisciplinary team continuously develops solutions that enhance quality of life and redefine standards in MedTech.At SÆPTUM, we listen, we innovate, we care.
Reliant Glycosciences
Reliant Glycosciences, LLC is a biotechnology company dedicated to developing diagnostic and prognostic tools for patients with IgA nephropathy (IgAN). The company’s objective is to create marketable assays for IgAN-specific biomarkers, making them accessible to both the IgAN research community and pharmaceutical companies interested in developing treatments for this condition. Reliant offers its own GalD Assay, which measures the level of galactose-deficient IgA1 (Gd-IgA1) in human serum samples. This assay is quantitatively assessed using a lectin-based ELISA test. Reliant aims to make a meaningful impact on the disease and its treatment.
QuidelOrtho
QuidelOrtho develops and manufactures intelligent solutions that are transforming the power of diagnostics into a healthier future for all, helping spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence. Together, we are transforming the power of diagnostics into a healthier future for all. | QuidelOrtho MicroVue Complement system products are a well-established name in immune system monitoring, providing a variety of first-in-class diagnostic and research solutions. The SPG product portfolio includes ELISA assays, multiplex, antibodies, proteins and sera-based products such as depleted sera, normal human serum and cobra venom factor.
ProKidney
ProKidney’s technology has the potential to preserve kidney function by using the patient’s own (autologous) kidney cells to potentially avoid or delay the need for dialysis.
Panoramic Health
Panoramic Health is kidney care’s leading integrated provider group, with 600+ providers across 15 states caring for 330,000+ CKD and ESKD patients. It is our mission to improve outcomes for patients by slowing disease progression and improving quality of life. We are more than a practice management company—we are a data-driven, physician-led platform providing a comprehensive suite of strategic, operational, and financial resources to empower nephrologists to deliver exceptional clinical outcomes while achieving long-term economic success.